Clinical Research Directory

Inclusion Criteria: Participants may be included in the study only if they meet all of the following criteria: 1. Healthy children aged between 3-6 months without medical disorders that contradict topical statin treatment. 2. Infants with newly diagnosed superficial IH. \[3\] Participants must possess at least one IH lesion with the longest diameter equal to or greater than 1 cm but less than 1% BSA, located on any part of the body except the lips. \[4\] Written informed consent from the parent(s)/guardian(s) must be obtained before any study procedure is performed. \[5\] Parent(s)/guardian(s) are willing to comply with the study protocol Exclusion Criteria: Participants meeting any of the following criteria will not be eligible to participate in the study: 1. IH is primarily characterized as subcutaneous, and deep, with minimal cutaneous involvement for evaluation. 2. IH with active ulceration at screening visit. 3. IH to be treated involving the lips mainly. 4. IH with high-risk criteria that need systemic propranolol treatment to avoid the delay with standard treatment 5. Participants with concurrent skin conditions that may impede accurate clinical assessment of the IH. 6. Participants with hereditary or metabolic disorders requiring systemic statin therapy. 7. Participants who are allergic to statins, or other ingredients present in the topical medication. 8. Participants who have received any of the following treatments for their IH: i) Topical medical therapy, i.e. imiquimod, sirolimus, timolol, intermediate or high strength steroids, etc. within the past 4 weeks ii) Systemic medical therapy, i.e. beta blockers, steroids, sirolimus for IH within the past 3 months iii) Surgical intervention including laser treatment within the past 6 weeks